CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland; Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.
CÚRAM, SFI Research Centre for Medical Devices, University of Galway, Galway, Ireland; Neurobiology Sector, International School for Advanced Studies (SISSA), Trieste, Italy.
Trends Mol Med. 2024 Feb;30(2):178-196. doi: 10.1016/j.molmed.2023.11.013. Epub 2023 Dec 22.
Protein glycosylation controls cell-cell and cell-extracellular matrix (ECM) communication in immune, vascular, and inflammatory processes, underlining the critical role of this process in the identification of disease biomarkers and the design of novel therapies. Emerging evidence highlights the critical role of blood cell glycosylation in the pathophysiology of atherosclerosis (ATH) and myocardial infarction (MI). Here, we review the role of glycosylation in the interplay between blood cells, particularly erythrocytes, and endothelial cells (ECs), highlighting the involvement of this critical post/cotranslational modification in settings of cardiovascular disease (CVD). Importantly, we focus on emerging preclinical studies and clinical trials based on glycan-targeted drugs to validate their therapeutic potential. These findings may help establish new trends in preventive medicine and delineate novel targeted therapies in CVD.
蛋白质糖基化控制着免疫、血管和炎症过程中的细胞-细胞和细胞-细胞外基质（ECM）通讯，这突显了该过程在疾病生物标志物的识别和新型治疗方法的设计中的关键作用。新出现的证据强调了血细胞糖基化在动脉粥样硬化（ATH）和心肌梗死（MI）病理生理学中的关键作用。在这里，我们综述了糖基化在血细胞，特别是红细胞和内皮细胞（EC）之间相互作用中的作用，强调了这种关键的翻译后/共翻译修饰在心血管疾病（CVD）中的参与。重要的是，我们专注于基于聚糖靶向药物的新兴临床前研究和临床试验，以验证它们的治疗潜力。这些发现可能有助于在预防医学中确立新趋势，并描绘 CVD 中的新型靶向治疗方法。
